BCRX BioCryst Pharmaceuticals
- 6.465
- +0.105+1.65%
BioCryst Pharmaceuticals News
Sector Update: Health Care Stocks Advance Late Wednesday Afternoon
Health care stocks were rising late Wednesday afternoon, with the NYSE Health Care Index up 1% and the Health Care Select Sector SPDR Fund (XLV) adding 1.2%. The iShares Biotechnology ETF (IBB) climbe
BioCryst Pharmaceuticals Shares Rise 20% Following Disclosure of Executive Share Purchases
BioCryst Pharmaceuticals (BCRX) shares were up nearly 20% in recent trading after the company reported in regulatory filings Wednesday that several of its executives purchased shares in the company ea
BioCryst Pharmaceuticals Form 4 Filings Shows CCO Charles K Gayer Bought 30,000 Shares At An Average Price Of $5.47/Share; CEO Jon P Stonehouse Bought 30,000 Shares At An Average Price Of $5.55/Share; Steven K Galson Bought 21,940 Shares At An Average...
BioCryst Pharmaceuticals Form 4 Filings Shows CCO Charles K Gayer Bought 30,000 Shares At An Average Price Of $5.47/Share; CEO Jon P Stonehouse Bought 30,000 Shares At An Average Price Of $5.55/Share;
Insider Buying: Chief R&D Officer Helen Thackray Acquires 30,000 Shares of BioCryst ...
Director Steven Galson Acquires 21,940 Shares of BioCryst Pharmaceuticals Inc (BCRX)
Insider Buying: CFO Anthony Doyle Acquires Shares of BioCryst Pharmaceuticals Inc (BCRX)
NEXTracker Posts Upbeat Earnings, Joins Monday.com, Nu Holdings And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones gaining around 150 points on Wednesday.Shares of Nextracker Inc. (NASDAQ:NXT) rose sharply during Wednesday's session after the company reported better-than
BioCryst Spikes After a Series of Insider Purchases
Biocryst Pharmaceuticals, T2 Biosystems, Annovis Bio Among Healthcare Movers
OPEN, BCRX and AWIN Among Pre-market Gainers
BioCryst Pharmaceuticals(BCRX.US) Officer Buys US$202.19K in Common Stock
$BioCryst Pharmaceuticals(BCRX.US)$ Officer Doyle Anthony purchased 36,300 shares of common stock on May 14, 2024 at an average price of $5.57 for a total value of $202.19K.Source: Announcement What i
BioCryst Pharmaceuticals(BCRX.US) Officer Buys US$175.8K in Common Stock
$BioCryst Pharmaceuticals(BCRX.US)$ Officer Thackray Helen M. purchased 30,000 shares of common stock on May 14, 2024 at an average price of $5.86 for a total value of $175.8K.Source: Announcement Wha
BioCryst Pharmaceuticals(BCRX.US) Director Buys US$120.45K in Common Stock
$BioCryst Pharmaceuticals(BCRX.US)$ Director Galson Steven K purchased 21,940 shares of common stock on May 13, 2024 at an average price of $5.49 for a total value of $120.45K.Source: Announcement Wha
BioCryst Pharmaceuticals(BCRX.US) Officer Buys US$27,650 in Common Stock
$BioCryst Pharmaceuticals(BCRX.US)$ Officer Barnes Alane P purchased 5,000 shares of common stock on May 13, 2024 at an average price of $5.53 for a total value of $27,650.Source: Announcement What is
BioCryst Pharmaceuticals(BCRX.US) Officer Buys US$164.1K in Common Stock
$BioCryst Pharmaceuticals(BCRX.US)$ Officer Gayer Charles K purchased 30,000 shares of common stock on May 13, 2024 at an average price of $5.47 for a total value of $164.1K.Source: Announcement What
BioCryst Pharmaceuticals(BCRX.US) Officer Buys US$166.5K in Common Stock
$BioCryst Pharmaceuticals(BCRX.US)$ Officer Stonehouse Jon P purchased 30,000 shares of common stock on May 13, 2024 at an average price of $5.55 for a total value of $166.5K.Source: Announcement What
BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology
RESEARCH TRIANGLE PARK, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) today announced that new data on oral, once-daily ORLADEYO (berotralstat) for the prophylactic treatment
BioCryst Says Orladeyo Granted Approval in Mexico
BioCryst Pharmaceuticals (BCRX) said Monday that it has received approval for Orladeyo from Mexico's Federal Commission for Protection against Health Risks for the prophylaxis of hereditary angioedema
ORLADEYO (Berotralstat) Approved in Mexico
RESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Federal Commission for Protection against Health Risks (COFEPRIS) in Mexico has
Here's What Analysts Are Forecasting For BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) After Its First-Quarter Results
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) just released its quarterly report and things are looking bullish. Revenues beat expectations coming in atUS$93m, ahead of estimates by 8.5%. Statutor
Analysis
Price Target
No Data
